219 related articles for article (PubMed ID: 28196419)
1. Why Monitor Molecules in Neuroscience?
Andrews AM
ACS Chem Neurosci; 2017 Feb; 8(2):211-212. PubMed ID: 28196419
[No Abstract] [Full Text] [Related]
2. [Psychopharmaceuticals as instruments for research].
Vinar O
Cesk Psychiatr; 1988 Feb; 84(1):28-35. PubMed ID: 2896551
[No Abstract] [Full Text] [Related]
3. Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin.
Greenshaw AJ
J Psychiatry Neurosci; 2003 Jul; 28(4):247-50. PubMed ID: 12921219
[No Abstract] [Full Text] [Related]
4. [The pharmacological properties of calcium channel blockers and the outlook for their use in psychiatry and neurology].
Kozlovskiĭ VL
Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(1):104-8. PubMed ID: 8009924
[No Abstract] [Full Text] [Related]
5. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
Schade S; Paulus W
Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26364274
[TBL] [Abstract][Full Text] [Related]
6. [Neurotransmitters and behavioral disorders].
Allain H; Schuck S
Encephale; 1998 Jul; 24 Spec No 1():34-7. PubMed ID: 9809253
[No Abstract] [Full Text] [Related]
7. Why drugs and hormones may interact in psychiatric disorders.
Stahl SM
J Clin Psychiatry; 2001 Apr; 62(4):225-6. PubMed ID: 11379834
[No Abstract] [Full Text] [Related]
8. New psychoactive drugs.
Murray JB
Genet Soc Gen Psychol Monogr; 1985 Nov; 111(4):429-53. PubMed ID: 2873081
[TBL] [Abstract][Full Text] [Related]
9. [Off-label use of drugs in psychiatry and neurology].
Wallesch CW
Fortschr Neurol Psychiatr; 2004 May; 72(5):243-4. PubMed ID: 15136944
[No Abstract] [Full Text] [Related]
10. European Neuroscience - Sixth Biennial FENS Forum.
Hannan AJ
IDrugs; 2008 Sep; 11(9):643-5. PubMed ID: 18763213
[No Abstract] [Full Text] [Related]
11. Psychotropic drugs in the elderly: principles of use.
Crismon ML
Am Pharm; 1990 Dec; NS30(12):57-63. PubMed ID: 2275456
[No Abstract] [Full Text] [Related]
12. [Old and new thought concepts on the biochemical principles of psychopharmcotherapy].
Wunderlich H; Wunderlich HP
Samml Zwangl Abh Geb Psychiatr Neurol; 1982; 50():61-80. PubMed ID: 6130615
[No Abstract] [Full Text] [Related]
13. Stereopsychopharmacology: past, present and future.
Smith DF
Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(3):327-50. PubMed ID: 6091180
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in neurobiology: Part III. Effectors of transmitter action.
Hyman SE
Psychosomatics; 1988; 29(4):373-8. PubMed ID: 2906447
[No Abstract] [Full Text] [Related]
15. Connecting Brain Proteomics with Behavioural Neuroscience in Translational Animal Models of Neuropsychiatric Disorders.
Sarnyai Z; Guest PC
Adv Exp Med Biol; 2017; 974():97-114. PubMed ID: 28353227
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Fischer A
Drug Res (Stuttg); 2017 Nov; 67(S 01):S9. PubMed ID: 29069674
[No Abstract] [Full Text] [Related]
17. [The future of biological psychiatry].
Linnoila M
Duodecim; 1985; 101(17):1732-7. PubMed ID: 2865128
[No Abstract] [Full Text] [Related]
18. Seventeenth Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, 11-13 December 1978--abridged proceedings.
Psychopharmacol Bull; 1980 Jan; 16(1):21-67. PubMed ID: 6102398
[No Abstract] [Full Text] [Related]
19. Strategies to Address Challenges in Neuroscience Drug Discovery and Development.
O'Donnell P; Rosen L; Alexander R; Murthy V; Davies CH; Ratti E
Int J Neuropsychopharmacol; 2019 Jul; 22(7):445-448. PubMed ID: 31139821
[TBL] [Abstract][Full Text] [Related]
20. Drugs prohibition is criminals' gain, neuroscience's loss.
Gross M
Curr Biol; 2013 Jul; 23(14):R585-8. PubMed ID: 24046855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
